FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170192548> ?p ?o ?g. }

• W2170192548 endingPage "8776" @default.
• W2170192548 startingPage "8766" @default.
• W2170192548 abstract "Although PS-341 (bortezomib) is a promising agent to improve multiple myeloma (MM) patient outcome, 65% of patients with relapsed and refractory disease do not respond. We have previously shown that heat shock protein (Hsp)27 is upregulated after PS-341 treatment, that overexpression of Hsp27 confers PS-341 resistance, and that inhibition of Hsp27 overcomes PS-341 resistance. Since Hsp27 is a downstream target of p38 mitogen-activated protein kinase (MAPK)/MAPK-mitogen-activated protein kinase-2 (MAPKAPK2), we hypothesized that inhibition of p38 MAPK activity could augment PS-341 cytotoxicity by downregulating Hsp27. Although p38 MAPK inhibitor SCIO-469 (Scios Inc, CA, USA) alone did not induce significant growth inhibition, it blocked baseline and PS-341-triggered phosphorylation of p38 MAPK as well as upregulation of Hsp27, associated with enhanced cytotoxicity in MM.1S cells. Importantly, SCIO-469 enhanced phosphorylation of c-Jun NH2-terminal kinase (JNK) and augmented cleavage of caspase-8 and poly(ADP)-ribose polymerase. Moreover, SCIO-469 downregulated PS-341-induced increases in G2/M-phase cells, associated with downregulation of p21Cip1 expression. Importantly, SCIO-469 treatment augmented cytotoxicity of PS-341 even against PS-341-resistant cell lines and patient MM cells. These studies therefore provide the framework for clinical trials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient outcome in MM." @default.
• W2170192548 created "2016-06-24" @default.
• W2170192548 creator A5003058860 @default.
• W2170192548 creator A5006765393 @default.
• W2170192548 creator A5007023688 @default.
• W2170192548 creator A5012712111 @default.
• W2170192548 creator A5019802024 @default.
• W2170192548 creator A5032464400 @default.
• W2170192548 creator A5033718619 @default.
• W2170192548 creator A5036686692 @default.
• W2170192548 creator A5043526996 @default.
• W2170192548 creator A5045740077 @default.
• W2170192548 creator A5050261399 @default.
• W2170192548 creator A5052048627 @default.
• W2170192548 creator A5059167270 @default.
• W2170192548 creator A5063862150 @default.
• W2170192548 creator A5078691986 @default.
• W2170192548 creator A5091207345 @default.
• W2170192548 date "2004-10-11" @default.
• W2170192548 modified "2023-10-18" @default.
• W2170192548 title "p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells" @default.
• W2170192548 cites W1520422891 @default.
• W2170192548 cites W1549679997 @default.
• W2170192548 cites W1570439864 @default.
• W2170192548 cites W1587892340 @default.
• W2170192548 cites W1977348505 @default.
• W2170192548 cites W1978518304 @default.
• W2170192548 cites W1980471295 @default.
• W2170192548 cites W1985442655 @default.
• W2170192548 cites W1994418770 @default.
• W2170192548 cites W2007998678 @default.
• W2170192548 cites W2011485061 @default.
• W2170192548 cites W2013192515 @default.
• W2170192548 cites W2016302829 @default.
• W2170192548 cites W2023312698 @default.
• W2170192548 cites W2043049816 @default.
• W2170192548 cites W2056769035 @default.
• W2170192548 cites W2057942504 @default.
• W2170192548 cites W2058804306 @default.
• W2170192548 cites W2070739194 @default.
• W2170192548 cites W2072493113 @default.
• W2170192548 cites W2076810768 @default.
• W2170192548 cites W2086575226 @default.
• W2170192548 cites W2108235071 @default.
• W2170192548 cites W2115541224 @default.
• W2170192548 cites W2118310862 @default.
• W2170192548 cites W2122578071 @default.
• W2170192548 cites W2137819605 @default.
• W2170192548 cites W2146502962 @default.
• W2170192548 cites W2152065071 @default.
• W2170192548 cites W2168268910 @default.
• W2170192548 cites W2168275907 @default.
• W2170192548 cites W2169210465 @default.
• W2170192548 cites W2315298535 @default.
• W2170192548 cites W2324088026 @default.
• W2170192548 cites W29946730 @default.
• W2170192548 cites W4245229780 @default.
• W2170192548 cites W4253333589 @default.
• W2170192548 cites W91158829 @default.
• W2170192548 doi "https://doi.org/10.1038/sj.onc.1208118" @default.
• W2170192548 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15480425" @default.
• W2170192548 hasPublicationYear "2004" @default.
• W2170192548 type Work @default.
• W2170192548 sameAs 2170192548 @default.
• W2170192548 citedByCount "122" @default.
• W2170192548 countsByYear W21701925482012 @default.
• W2170192548 countsByYear W21701925482013 @default.
• W2170192548 countsByYear W21701925482014 @default.
• W2170192548 countsByYear W21701925482015 @default.
• W2170192548 countsByYear W21701925482017 @default.
• W2170192548 countsByYear W21701925482018 @default.
• W2170192548 countsByYear W21701925482019 @default.
• W2170192548 countsByYear W21701925482020 @default.
• W2170192548 countsByYear W21701925482021 @default.
• W2170192548 countsByYear W21701925482022 @default.
• W2170192548 countsByYear W21701925482023 @default.
• W2170192548 crossrefType "journal-article" @default.
• W2170192548 hasAuthorship W2170192548A5003058860 @default.
• W2170192548 hasAuthorship W2170192548A5006765393 @default.
• W2170192548 hasAuthorship W2170192548A5007023688 @default.
• W2170192548 hasAuthorship W2170192548A5012712111 @default.
• W2170192548 hasAuthorship W2170192548A5019802024 @default.
• W2170192548 hasAuthorship W2170192548A5032464400 @default.
• W2170192548 hasAuthorship W2170192548A5033718619 @default.
• W2170192548 hasAuthorship W2170192548A5036686692 @default.
• W2170192548 hasAuthorship W2170192548A5043526996 @default.
• W2170192548 hasAuthorship W2170192548A5045740077 @default.
• W2170192548 hasAuthorship W2170192548A5050261399 @default.
• W2170192548 hasAuthorship W2170192548A5052048627 @default.
• W2170192548 hasAuthorship W2170192548A5059167270 @default.
• W2170192548 hasAuthorship W2170192548A5063862150 @default.
• W2170192548 hasAuthorship W2170192548A5078691986 @default.
• W2170192548 hasAuthorship W2170192548A5091207345 @default.
• W2170192548 hasBestOaLocation W21701925481 @default.
• W2170192548 hasConcept C104317684 @default.
• W2170192548 hasConcept C109316439 @default.
• W2170192548 hasConcept C127561419 @default.
• W2170192548 hasConcept C153911025 @default.

• next